{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:47:09Z","timestamp":1777520829920,"version":"3.51.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1097\/coc.0b013e3182a4676b","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T11:24:42Z","timestamp":1376047482000},"page":"315-321","source":"Crossref","is-referenced-by-count":24,"title":["Emerging Therapies in Multiple Myeloma"],"prefix":"10.1097","volume":"38","author":[{"given":"Joelle","family":"El-Amm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad A.","family":"Tabbara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-15-20210128","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1182\/blood-2009-07-204651","article-title":"How I treat multiple myeloma in younger patients.","volume":"114","author":"Stewart","year":"2009","journal-title":"Blood"},{"key":"R2-15-20210128","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma.","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"R3-15-20210128","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":". Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"R4-15-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CE.S13838","article-title":". Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.","volume":"6","author":"Jain","year":"2011","journal-title":"Core Evid"},{"key":"R5-15-20210128","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":". Proteasome inhibitors in multiple myeloma: 10 years later.","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"R6-15-20210128","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":". A phase I dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.","volume":"15","author":"OConnor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R7-15-20210128","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":". A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"R8-15-20210128","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":". An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed andor refractory multiple myeloma.","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"R12-15-20210128","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":". A phase 12 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"R13-15-20210128","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":". International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"R20-15-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","article-title":". Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.","volume":"17","author":"Lentzsch","year":"2003","journal-title":"Leukemia"},{"key":"R21-15-20210128","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":". Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD 34 progenitor cells.","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"key":"R22-15-20210128","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":". Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"R23-15-20210128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":". Mechanism of action of immunomodulatory (IMiDS) in multiple myeloma.","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"R24-15-20210128","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":". Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.","volume":"22","author":"Schey","year":"2004","journal-title":"J Clin Oncol"},{"key":"R25-15-20210128","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","article-title":". Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.","volume":"107","author":"Anderson","year":"2006","journal-title":"Blood"},{"key":"R27-15-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07013.x","article-title":". Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.","volume":"141","author":"Streetly","year":"2008","journal-title":"Br J Haematol"},{"key":"R28-15-20210128","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":". Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"key":"R30-15-20210128","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":". Pomalidomide (CC4047) plus low dose dexamethasone (Pomdex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"key":"R33-15-20210128","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":". Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease.","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"key":"R40-15-20210128","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V120.21.LBA-6.LBA-6","article-title":". Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsedrefractory MM: a phase 3, multicenter, randomized, open-label study.","volume":"120","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"R41-15-20210128","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","article-title":"The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.","volume":"30","author":"Anderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"R42-15-20210128","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":". CS1, a potential new therapeutic antibody target for the treatment for multiple myeloma.","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R43-15-20210128","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":". Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"R44-15-20210128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1034\/j.1600-065X.2001.1810120.x","article-title":". 2B4 (CD244) and CS1: novel members of the CD2subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes.","volume":"181","author":"Boles","year":"2001","journal-title":"Immunol Rev"},{"key":"R46-15-20210128","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":". Combinational efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.","volume":"8","author":"Van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"R48-15-20210128","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":". Elotuzumab in combination with lenalidomide and lowdose dexamethasone in relapsed or refractory multiple myeloma.","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol"},{"key":"R51-15-20210128","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":". Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsedrefractory multiple myeloma.","volume":"30","author":"Jakubowiak","year":"2011","journal-title":"J Clin Oncol"},{"key":"R53-15-20210128","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":". Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.","volume":"107","author":"Hideshima","year":"2006","journal-title":"Blood"},{"key":"R54-15-20210128","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1158\/1078-0432.CCR-08-0016","article-title":". Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.","volume":"14","author":"David","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R55-15-20210128","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.2007.06714.x","article-title":". Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.","volume":"138","author":"Hideshima","year":"2007","journal-title":"Br J Haematol"},{"key":"R56-15-20210128","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1200\/JCO.2010.33.9788","article-title":". Perifosine plus bortezomib and dexamethasone in patients with relapsedrefractory multiple myeloma previously treated with bortezomib: results of a multicenter phase III trial.","volume":"29","author":"Richardson","year":"2011","journal-title":"J Clin Oncol"},{"key":"R59-15-20210128","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":". Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"key":"R60-15-20210128","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3109\/10428194.2012.661175","article-title":". A phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsedrefractory multiple myeloma.","volume":"53","author":"Wolf","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R61-15-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): success and challenges.","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0b013e3182a4676b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T19:55:58Z","timestamp":1688414158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201506000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3182a4676b","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}